GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Guerbet SA (GREY:GUERF) » Definitions » EV-to-EBITDA

Guerbet (Guerbet) EV-to-EBITDA : 4.20 (As of May. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Guerbet EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Guerbet's enterprise value is $481.2 Mil. Guerbet's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $114.6 Mil. Therefore, Guerbet's EV-to-EBITDA for today is 4.20.

The historical rank and industry rank for Guerbet's EV-to-EBITDA or its related term are showing as below:

GUERF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.07   Med: 7.8   Max: 13.8
Current: 7.3

During the past 13 years, the highest EV-to-EBITDA of Guerbet was 13.80. The lowest was 4.07. And the median was 7.80.

GUERF's EV-to-EBITDA is ranked better than
81.48% of 486 companies
in the Medical Devices & Instruments industry
Industry Median: 16.29 vs GUERF: 7.30

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-15), Guerbet's stock price is $22.25. Guerbet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000. Therefore, Guerbet's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Guerbet EV-to-EBITDA Historical Data

The historical data trend for Guerbet's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guerbet EV-to-EBITDA Chart

Guerbet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.67 7.33 6.96 4.45 5.23

Guerbet Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.96 - 4.45 - 5.23

Competitive Comparison of Guerbet's EV-to-EBITDA

For the Medical Devices subindustry, Guerbet's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guerbet's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Guerbet's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Guerbet's EV-to-EBITDA falls into.



Guerbet EV-to-EBITDA Calculation

Guerbet's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=481.229/114.605
=4.20

Guerbet's current Enterprise Value is $481.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Guerbet's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $114.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Guerbet  (GREY:GUERF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Guerbet's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=22.25/0.000
=N/A

Guerbet's share price for today is $22.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Guerbet's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Guerbet EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Guerbet's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Guerbet (Guerbet) Business Description

Traded in Other Exchanges
Address
15 rue des Vanesses, Zone Paris Nord II, Villepinte, FRA, 93420
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.

Guerbet (Guerbet) Headlines

From GuruFocus